EWP
BIO icon

Elevation Wealth Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Elevation Wealth Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Sell
4
-15
-79% -$4.25K ﹤0.01% 1246
2026
Q1 		$5.3K Buy
+19
New +$5.47K ﹤0.01% 696
2024
Q3 		– Sell
-9
Closed -$2.46K – 485
2024
Q2 		$2.46K Buy
+9
New +$2.62K ﹤0.01% 440

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Elevation Wealth Partners's BIO Position: Q2 2026 in Review

Elevation Wealth Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 79% in Q2 2026, selling an estimated $4.25K and leaving 4 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

Elevation Wealth Partners first reported a position in BIO in Q2 2024 and has held it in 3 quarters since. The position peaked at $5.3K in Q1 2026. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Elevation Wealth Partners held 4 shares of Bio-Rad Laboratories Class A worth $1.18K as of Q2 2026.
  • Elevation Wealth Partners sold 15 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $4.25K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #1246 holding.
  • Elevation Wealth Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2024 and has held it in 3 quarters since.
  • Elevation Wealth Partners's Bio-Rad Laboratories Class A position peaked at $5.3K in Q1 2026.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.